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Background. Patients with glioblastoma multiforme (GBM) have an overall median survival of 15 months. This catastrophic survival
rate is the consequence of systematic relapses that could arise from remaining glioblastoma stem cells (GSCs) left behind after sur-
gery. We previously demonstrated that GSCs are able to escape the tumor mass and specifically colonize the adult subventricular
zones (SVZs) after transplantation. This specific localization, away from the initial injection site, therefore represents a high-quality
model of a clinical obstacle to therapy and relapses because GSCs notably retain the ability to form secondary tumors.
Method. In this work, we questioned the role of the CXCL12/CXCR4 signaling in the GSC-specific invasion of the SVZs.
Results. We demonstrated that both receptor and ligand are respectively expressed by different GBM cell populations and by the SVZ
itself. In vitro migration bio-assays highlighted that human U87MG GSCs isolated from the SVZs (U87MG-SVZ) display stronger mi-
gratory abilities in response to recombinant CXCL12 and/or SVZ-conditioned medium (SVZ-CM) compared with cancer cells isolated
from the tumor mass (U87MG-TM). Moreover, in vitro inhibition of the CXCR4 signaling significantly decreased the U87MG-SVZ cell
migration in response to the SVZ-CM. Very interestingly, treating U87MG-xenografted mice with daily doses of AMD3100, a specific
CXCR4 antagonist, prevented the specific invasion of the SVZ. Another in vivo experiment, using CXCR4-invalidated GBM cells, dis-
played similar results.
Conclusion. Taken together, these data demonstrate the significant role of the CXCL12/CXCR4 signaling in this original model of brain
cancer invasion.
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Primary brain tumors are among the most refractory of malig-
nancies. Their most aggressive form, glioblastoma multiform
(GBM, WHO grade IV), is also the most common and lethal sub-
type.1 Although multimodal therapies have been developed,
the overall median survival of GBM patients hardly reaches 15
months from the time of diagnosis.2 This poor survival rate is
the consequence of tumor recurrence that systematically oc-
curs despite classical therapeutic strategies. Trying to under-
stand the origin of GBM relapses seems mandatory, in this
context, for a better understanding of the tumor’s biology
and improving the patients’ quality of life.
The infiltrative patterns of GBM make tumor cells hard to tar-
get. Furthermore, recent studies using orthotopic xenografts
have demonstrated that GBM cells are able to escape the
tumor mass and specifically invade the subventricular zones
(SVZs) of the adult brain.3,4 In that environment, GBM cells
were first shown to be highly tumorigenic and were later char-
acterized as glioblastoma stem cells (GSCs). The SVZ is known
to be the major source of neural stem cells and progenitors in
adults and functions as a supportive niche promoting self-
renewal and inhibits differentiation.5,6 This “seed-and-soil” rela-
tionship has also been adapted to cancer stem cell research
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because GSCs also rely on a specific environment or niche to
maintain their stem cell properties and their ability to drive
tumor growth.7,8
In this work, we questioned the role of the CXCL12/CXCR4
signaling in the GSC-oriented invasion of the SVZ. CXCR4 is
known to be expressed by highly malignant gliomas,9,10 be in-
volved in tumor cell proliferation,11 and be associated with a
poor survival.12 Recent studies have shown that CXCL12 and
CXCR4 enhance tumorigenesis through increased proliferation
of tumor cells13 and that CXCL12 boosts the release of vascular
endothelial growth factor (VEGF) from GSC, leading to tumor
growth-induced angiogenesis.14 When taken altogether,
those facts led to investigating the eventual role of the CXCR4
signaling in the specific invasion of the SVZ by human GSC.
Counteracting with the invasion abilities of GSC would make
those cells more easily targeted by classical therapeutic strat-




Primary GBM cultures (GBM1, GBM2, and GB138) were estab-
lished from consenting participants and validated as previously
described.3,15 Human GBM cell lines (U87MG ATCC HTB-14,
U373 [a generous gift from Florence Lefranc], and LN18 ATCC
CRL-2610) were cultivated in Dulbecco’s modified Eagle’s medi-
um (DMEM) containing 10% fetal bovine serum (Invitrogen).
Details can be found in Supplemental Experimental Procedures.
Ethics Statement
Participants gave their informed consent for use of GBM speci-
mens. The use of human tissue has been allowed by the “Com-
ite´ d’e´thique Hospitalo-Universitaire du CHU de Lie`ge”. This use
concerns only residual material after surgical tumor ressection.
Animals
Adult P40 female immunodeficient nude mice, Crl:NU-Foxn1nu,
obtained from Charles River Laboratories, were used for xeno-
grafts and ventricular surface studies. All animals were cared
for in accordance with the Declaration of Helsinki and following
the guidelines of the Belgium Ministry of Agriculture in agree-
ment with European Commission Laboratory Animal Care and
Use Regulation (86/609/CEE, CE of J n_L358, 18 December
1986). The athymic nude mice were housed in sterilized, filter-
topped cages and were processed as approved by the Animal
Ethical Committee of the University of Lie`ge.
Whole Mount Dissection
The lateral walls of the ventricles were dissected from the cau-
dal aspect of the telencephalon, as previously described.16 De-
tailed procedures can be found in Supplemental Experimental
Procedures.
Intracranial Transplantation
Intracranial xenografts were generated, as described previous-
ly.3 Detailed procedures can be found in Supplemental Experi-
mental Procedures.
In Vitro Migration Bio-assays
Chemotaxis assays were performed using a 96-well chemotax-
is chamber with 10 mm pore size (NeuroProbe). GBM cell lines
were labeled using a Cell Tracker Green (CTG) dye (Invitrogen)
at a final concentration of 5 mM in prewarmed DMEM for
30 minutes. The medium was replaced with DMEM and incu-
bated for 30 minutes at 378C. Cells were washed 3 times with
phosphate-buffered saline (PBS) and seeded in the upper
chamber (25 000 cells in 25 ml of serum-free medium without
growth factors). The lower chamber was filled with 28 ml of
serum-free medium, SVZ-conditioned medium,
SVZ-conditioned medium containing AMD3100 (25 mg/ml,
Sigma), or serum-free medium with different concentrations
of human recombinant CXCL12 (Peprotech). After incubation
at 378C for 16 hours, cells in the lower chambers were fixed
with 4% paraformaldehyde (PFA) for 15 minutes. Chambers
were rinsed, and the total number of migrating cells was quan-
tified by counting the number of CTG-positive cells per well (n¼
3) for each condition.
Time-lapse Analysis
Live chemotaxis was measured by means of m-Slides (Ibidi
GmbH) according to the manufacturer’s instructions.17 De-
tailed procedures can be found in Supplemental Experimental
Procedures.
Western Blot Analysis
Protein extracts were resolved with Novex 10% Bis-Tris gels
(NuPAGE, Invitrogen) and transferred onto a PVDF membrane
(Roche) according to standard protocols. Blots were then
probed with primary and secondary antibodies. Blots were im-
aged with the ImageQuant 350 scanning system (cooled-CCD
camera, GE Healthcare). Detailed procedures and buffer com-
position can be found in Supplemental Experimental
Procedures.
Gene Expression Profiling Using Real-time PCR Arrays
SVZs were dissected as previously described (n¼ 12), and total
RNA was isolated using Trizol reagent (Invitrogen) and then re-
purified using a column (RNeasy Mini Kit; Qiagen) according to
the manufacturer’s protocol. PCR array analysis was performed
using RT2 profiler PCR array (mouse chemokines and cytokines,
PAMM-150, SABiosciences). Detailed procedures can be found
in Supplemental Experimental Procedures.
Real-time PCR
Total RNA was isolated using the RNeasy Mini Kit (Qiagen) ac-
cording to the manufacturer’s protocol. Detailed procedures
can be found in Supplemental Experimental Procedures.
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Processing of Tissue Sections and Cell Cultures Before
Immunostaining
Mice were anesthetized with an injection of Nembutal (pento-
barbital 60 mg/mL, Ceva Sante Animal) before an intracardiac
perfusion with a NaCl 0.9% solution (Prolabo, VWR Internation-
al) followed by 4% PFA at 48C (4,3 g/L NaOH, 40 g/L paraformal-
dehyde, 18.8 g/L NaH2PO4). Brains were collected, postfixed in
4% PFA, and cryoprotected overnight in a solution of PBS/
sucrose (20%). Brains were frozen at 2208C in a
2-methylbutane solution (Sigma) and cut into 16 mm thick co-
ronal sections using a cryostat. For immunocytofluorescence,
cells were placed on coverslips previously coated with polyorni-
thine for 3 hours (0.1 mg/mL, Sigma). Cells were washed in PBS,
fixed in 4% PFA for 15 minutes, and washed in PBS.
Immunostaining
Brain coronal sections or GBM cells were permeabilized, and un-
specific binding sites were blocked using 10% donkey serum
and 0.1% Triton X-100 PBS solution. Tissue sections or cells
were incubated with primary antibodies diluted in PBS contain-
ing 0.1% donkey serum and 0.1% Triton X-100, followed by a
second incubation with RRX- or FITC-conjugated secondary an-
tibodies (1:500, Jackson Immunoresearch Laboratories). De-
tailed procedures can be found in Supplemental Experimental
Procedures.
Enzyme-linked Immunosorbent Assay Analysis
CXCL12 concentrations in SVZ/cerebellum/olfactory bulb (OB)-
conditioned medium were analyzed by sandwich enzyme-
linked immunosorbent assay (ELISA) according to the manu-
facturer’s instructions (R&D Systems).
Plasmids, Lentiviral Vectors Generation, and Transduction
Detailed information and procedures can be found in Supple-
mental Experimental Procedures.
Bioluminescence Imaging
Immunodeficient nude mice bearing intracranial xenografts
were injected intraperitoneally with D-luciferin (150 mg/kg,
Sigma). After anesthesia using 2.5% isoflurane, mice were im-
aged with a charge-coupled device camera-based biolumines-
cence imaging system (IVIS 50, Xenogen; exposure time 1–
30 s, binning 8, field of view 12, f/stop 1, open filter). Signals
were displayed as photons/s/cm2/sr. Regions of interest were
defined manually, and images were processed using Living
Image and IgorPro Software (Version 2.50). Raw data were ex-
pressed as total photon flux (photons/s).
Image Acquisition and Data Analysis
Immunostained sections were imaged using a laser-scanning
confocal microscope equipped with a krypton/argon gas layer
(Olympus Fluoview 1000). Zeiss Axiovert 10VR microscope
(Carl Zeiss), coupled with Mercator software (Explora Nova),
was used for cell counting and 3D reconstructions. Figures
were composed and examined using ImageJ.
Statistical Analysis
Quantitative data are expressed as mean+SEM. Two-way
ANOVA, followed by a Tukey posttest was used, and a P value
,0.05 was considered statistically significant. Student t tests
were performed for 2 groups were compared using Statistica
10.0 software.
Results
In Vivo Model of GSC Invasion
We previously demonstrated that human GSCs are able to in-
vade the SVZ environment once injected in the striatum of im-
munodeficient mice.3 Using this model of cancer cell invasion,
we grafted human primary GBM cells (GB138) expressing eGFP
in the striatum of mice tolerating xenografts. Twelve weeks
after the injection, as the mice developed tumors (TM), we iden-
tified primary GB138 cells in the SVZ environment. As expected,
those cells migrated along the corpus callosum (CC), one of the
main white matter structures connecting both left and right
hemispheres together (Fig. 1A). We then validated this specific
model of SVZ invasion with human U87MG cells, which were in-
jected into the striatum of immunodeficient mice as well. Three
weeks after the injections, we identified U87MG cells in the CC
of mice using specific antihuman nuclei antibodies (white ar-
rows, Fig. 1B). By the end of the fourth week after the graft,
human U87MG cells had colonized the SVZ environment, with
some of the cells retaining their ability to proliferate as shown
by a Ki67-positive staining (white arrows, Fig. 1C and C′). Relying
on this specific model of brain cancer invasion, we isolated
U87MG and GB138 cells from the TM (U87MG-TM and
GB138-TM) and from the SVZs (U87MG-SVZ and GB138-SVZ).
We tested the ability of those 4 cell subtypes to form glioma-
spheres (Fig. 1D). Being able to form gliomaspheres is indeed
part of the cancer stem cell definition.18 Interestingly, both
U87MG-SVZ and GB138-SVZ cells were better to grow as float-
ing spheres compared with U87MG-TM cells (P¼ .002) and
GB138-TM cells (P¼ .0001).
Expression of Chemokines in the SVZ Environment
In order to identify potential targets involved in the GSC-specific
invasion of the SVZ, we looked for soluble factors secreted by
the SVZ environment that could eventually play a role in this
migration phenotype. To do so, total mRNA extractions from
12 independent SVZ whole mounts were performed, and a
wide scale RT-qPCR array was conducted. This analysis high-
lighted high mRNA levels (Ccl12, Ccl19, Cxcl12 and Cx3cl1 - [yel-
low rim of the graph]), basal mRNA levels (Ccl5, Ccl17, Cxcl10
and Cxcl16 [purple rim of the graph]), and low mRNA levels
(Xcl1, Ccl1, Cxcl3 and Cxcl9 [white rim of the graph]) of cytokines
and chemokines present in the SVZ environment (Fig. 2A). This
database provides a “big picture” summary of the different fac-
tors that could be involved in the GSC-specific invasion of the
SVZ. From those data, we identified CXCL12 as the main target
of our study. Indeed, CXCL12 has already been shown to be
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involved in glioma cell proliferation.19,20 We first confirmed
CXCL12 mRNA expression on SVZ whole mounts, using mesen-
chymal stem cells as a positive control (Fig. 2B). We studied the
expression of CXCL12 on brain coronal sections of mice previ-
ously injected with human U87MG cells and highlighted a
close relationship between the expression of CXCL12 and the
presence of U87MG GSC in the SVZ (Fig. 2C). We confirmed
that observation on coronal sections of brains injected with
human GB138 primary cells labeled with eGFP (Fig. 2D and E).
We managed to put to light a gradient of CXCL12 within the SVZ
environment (Fig. 2F). To do so, we transformed each CXCL12
acquisition from the SVZ environment into binary images and
quantified the CXCL12 expression in predefined areas (A, SVZ;
B, transition SVZ-striatum; C, striatum). We systematically
found a constant decrease of the CXCL12 expression starting
from area A to C. This suggests that CXCL12 is mostly secreted
in the SVZ and diffuses towards the striatum along a decreasing
concentration gradient. To further explore the expression of
CXCL12, we decided to compare, by ELISA, the secretion of
CXCL12 within the SVZ with other regions of the brain such as
the cerebellum and the OBs. We found a significant increase of
the CXCL12 expression within the medium conditioned by SVZ
whole mounts for 60 hours compared with 24 hours (P¼
.0006). Moreover, a significantly higher amount of CXCL12
was found in the medium conditioned by SVZ whole mounts
for 60 hours compared with media conditioned either by OB
or cerebellum whole mounts for 60 hours (P¼ .005) (Fig. 2G).
This shows how specific the CXCL12 expression is to the SVZ re-
gion. We finally demonstrated that the blood vessels overlaying
the lateral wall of the ventricle (lectin staining) and the astro-
cytes (glial fibrillary acid protein [GFAP] staining) were sources
of CXCL12 in the adult brain (Fig. 2H).
Expression of CXCR4 by Human GBM Cells
We then tackled the expression of CXCL12 receptors on human
GBM cells. Using reverse transcription (RT-)PCR and Western
blot approaches, we highlighted the expression of CXCR4 on 3
GBM cell lines (U87MG, U373, and LN18) and 2 GBM cell popu-
lations in primary cultures (GBM1 and GBM2) (Fig. 3A and B). We
also checked the CXCR4 expression profile on U87MG cells,
U87MG cells isolated from the TM (U87MG-TM), U87MG cells
from the SVZ (U87MG-SVZ), and U87MG cells cultured as float-
ing spheres (U87MG NS). We noticed a comparable expression
of CXCR4 in each of these cell populations (Fig. 3C). We then
characterized the U87MG spheres for the expression of
CXCR4, together with immature markers and differentiation
markers. Immunostained spheres revealed that CXCR4 is main-
ly associated with proteins such as Nestin, Sox2, bIII-Tubulin,
and GFAP on GBM cells (Fig. 3D). We finally characterized glio-
maspheres from U87MG-TM and U87MG-SVZ cells and labeled
them with different GSC markers such as Prominin-1 (CD133) or
Integrin a6 (ITGA6).21 We demonstrated here that both glio-
masphere subpopulations expressed important levels of
CXCR4, Nestin, CD133, and ITGA6 (Fig. 3E).
We know that CXCL12 can bind a second chemokine recep-
tor, CXCR7.22 This recently discovered receptor is the center of
attention in many publications on GBM, but its role in tumori-
genesis remains unclear.23,24 As far as we are concerned, we
have not been able to detect a convincing CXCR7 expression
by immunohistofluorescence or Western blot analyses (data
not shown), making it unlikely to be involved in our model.
AMD3100 Disrupts Chemotactic Effects of
SVZ-conditioned Medium on GBM Cells
To investigate whether human GBM cells home to the SVZ
through secreted factors in a direct manner, we brought a
modified Boyden chamber assay into focus. Human GBM cells
were suspended in serum-free medium and seeded on top of a
porous membrane, separating them from a bottom chamber
filled with test or control media, which allowed the cells to
move into the bottom part of the chamber in response to the
chemotactic agent of interest. We first tested the ability of
U87MG cells to migrate in response to various concentrations
of CXCL12 and serial dilutions of SVZ-CM. U87MG cells displayed
a dose-dependent migration behavior in response to both stim-
ulations (Fig. 4A and C). To confirm the U87MG tropism towards
a gradient of CXCL12 and SVZ-CM, we seeded U87MG cells in
chemotaxis m-Slides. We then recorded and analyzed the
U87MG cell tracks over a period of 20 hours in response to
both stimulations. The overall distribution of migration angles
was analyzed and revealed significant clusters of migration di-
rection in response to the CXCL12 gradient (P, .001) (Fig. 4B)
and the SVZ-CM gradient (P¼ .0006) (Fig. 4D).
We then evaluated the impact of AMD3100 on the U87MG cell
migration using our modified Boyden chamber assays. CXCL12/
CXCR4 signaling can indeed be blocked using AMD3100,25 a bicy-
clam noncompetitive antagonist of CXCR4.26 Adding AMD3100
(25 nM) in the SVZ-CM was followed by a significant reduction
(228.2%) of the number of U87MG cells (P¼ .005) migrating
through the filter. AMD3100 also inhibited the migration abilities
of GBM primary cells in response to the SVZ-CM (238.6%, GBM2;
P¼ .0001) (Fig. 4E). The impact of AMD3100 was once again con-
firmed on U87MG cells using cell-track recordings and time-lapse
analyses. AMD3100 clearly disrupted the U87MG distribution of
migration angles in response to SVZ-CM (P¼ .697) (Fig. 4F) com-
pared with SVZ-CM alone (Fig. 4D). However, AMD3100 did not
impact the mean accumulated distance or velocity of U87MG
cells, suggesting that other chemokines in the SVZ-CM could
Fig. 1. Invasion of the subventricular zone (SVZ) by U87MG cells and GB138 primary cells after intrastriatal implantation. (A) Human GB138 cells
specifically colonized the SVZ environment after migration through the corpus callosum (CC). (B) Human U87MG cells invaded the largest part of
the right striatum 3 weeks after the graft. At this point, U87MG cells had already escaped the tumor mass (TM) and began to migrate along the CC
(white arrows). (C) U87MG cells finally invaded the SVZ environment 4 weeks after the injection, with some of them still being in a proliferation state
(white arrows, magnified square). (D) U87MG and GB138 cells isolated from the SVZ displayed stronger abilities to form gliomaspheres than U87MG
or GB138 cells isolated from the TM. Human U87MG cells were detected using an antihuman nuclei antibody (Hu. Nuclei - red). GB138 cells were
engineered to express the green fluorescent protein (eGFP - green). Cell nuclei were counterstained with DAPI (blue). Scale bars¼ 500 mm for B,
40 mm for A and C. ** P, .01, ***P, .001.
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also play a role in the in vitro U87MG migration behavior in re-
sponse to SVZ-CM (Fig. 4G and H).
We finally compared how U87MG cells, U87MG-TM cells (iso-
lated from the tumor mass), and U87MG-SVZ cells (isolated
from the SVZ) behaved in response to recombinant CXCL12 or
SVZ-CM supplemented or not with AMD3100. Surprisingly,
U87MG-SVZ cells displayed greater migration ability in response
to recombinant CXCL12 than U87MG cells or U87MG-TM cells
(P, .0001). Similarly, U87MG-SVZ cells were also more attract-
ed by the SVZ-CM in comparison with the other cell populations
(P, .0001). Interestingly, the in vitro inhibition of migration by
AMD3100 was also more obvious on the U87MG-SVZ cell pop-
ulation compared with their counterparts isolated from the
tumor mass. Using AMD3100 (25 nM) allowed to decrease
the U87MG-TM and U87MG-SVZ migration levels up to 17.7%
(not statistically significant) and 44.2% respectively (P,
.0001) (Fig. 4I), suggesting a stronger impact of the drug on
GBM cells isolated from the SVZ and previously characterized
as a population enriched in GSC abilities.3
Depletion of CXCR4 Inhibits the GSC Invasion of the SVZ
We generated stable CXCR4-invalidated U87MG cells using 2
different shRNA-mediated knockdowns. Those cells were also
engineered to express a fusion protein of firefly luciferase and
eGFP (U87MG-EIL-shCXCR4* and U87MG-EIL-shCXCR4**). Con-
trol cells for this experiment were built through expression of
a scrambled shRNA (U87MG-EIL-sc).
We first confirmed the depletion of CXCR4 by Western blot
analysis and validated those data by immunocytofluorescence
(Fig. 5A and B). The expression of CXCR4 was downregulated by
41% and 64%, respectively, in the U87MG-EIL-shCXCR4* and
U87MG-EIL-shCXCR4** cell populations (Fig. 5A). We then test-
ed the functionality of those 2 CXCR4-depleted cell populations
using modified Boyden chambers to evaluate chemotaxis in re-
sponse to recombinant CXCL12. The migration of both
CXCR4-depleted U87MG cells was significantly reduced, regard-
less of the remaining level of CXCR4 (Fig. 5C). We finally grafted
the 2 populations of CXCR4-depleted U87MG cells and U87MG
control cells into the striatum of immunodeficient mice. As ex-
pected, human U87MG cells, labeled with eGFP, were found in
the CC and the SVZ region of control mice after 4 weeks
(Fig. 5D). Surprisingly, this invasion phenotype was totally ham-
pered in the CXCR4 knockdown conditions, in which no eGFP sig-
nal could be detected in the SVZ environment (Fig. 5E). There
were no differences observed in mean body mass between
groups (data not shown).
AMD3100 Inhibits the Specific GSC Invasion of the SVZ
We injected luciferase-expressing U87MG cells into the right
striatum of immunodeficient nude mice. Animals bearing xeno-
grafts were separated into 2 homogeneous groups at day 25
post injection according to in vivo bioluminescence data. In-
deed, U87MG cells expressing the luciferase enzyme allowed
to monitor noninvasive imaging of tumor-associated biolumi-
nescence and quantification of tumor growth over time.27
Half of the cohort was treated twice a day with intraperitoneal
injections of AMD3100 at a concentration of 1.25 mg/kg,
whereas the other half of the cohort was treated with PBS (con-
trol). The treatment started at day 25 in order to minimize the
already-known impact of AMD3100 on tumor growth11 and,
more specifically, to treat the mice during the particular win-
dow of time when human GSC started to invade the SVZ.3
Growth curves established from serial measurements of biolu-
minescence revealed a significant antitumor effect of
AMD3100 in U87MG-xenografted mice (P, .01) (Fig. 6A). This
observation was consistent with the fact that tumor volumes
were on average 28% smaller in the AMD3100-treated group
after histological examinations (data not shown). This reduc-
tion of tumor volume was nevertheless not statistically signifi-
cant due to the high variability between animals bearing
xenografts (P¼ .65).
Regarding the invasive abilities of U87MG cells, the number
of GBM cells in the CC of AMD3100-treated animals was signifi-
cantly reduced compared with control animals (P, .001)
(Fig. 6B and C). More importantly, we were not able to detect
the presence of any U87MG cells in the SVZ environment of
AMD3100-treated animals (P, .01) (Fig. 6B and C). We then
showed that AMD3100 does not induce U87MG cell death in
xenografted animals after treatment (Supplementary data,
Fig. S2). In this way, we demonstrated that the inhibition of
SVZ invasion by U87MG GSC is CXCR4 dependent and not a con-
sequence of a loss of cell viability. On the other hand, U87MG
cells had left the tumor mass and specifically invaded the
SVZ environment through the CC in the control animals
(Fig. 6C).
Discussion
The hypothesis of cancer stem cells has often been proposed
to explain therapeutic failure and recurrence in a variety of
cancers including GBM.28 In this case, it has been suggested
that GSCs are both radioresistant29,30 and chemoresistant.31
Previously, we demonstrated that one of the known
Fig. 2. Expression of CXCL12 by the subventricular zone (SVZ) environment. (A) RT-qPCR screening notably displayed a high expression level of CXCL12
in the SVZ environment (yellow rim of the graph). (B) This observation was validated by RT-PCR using mesenchymal stem cells (MSC) as a positive
control. (C–E) The expression of CXCL12 was next demonstrated on brain coronal sections. This expression was consistent with the presence of
U87MG cells (Hu. Nuclei) or GB138 primary cells (eGFP) in the SVZ (white arrows). (F) CXCL12 acquisitions were processed as binary images. The
mean intensity, with foreground 255 and background 0, in predefined areas of the SVZ environment (A, B, and C) was calculated. A constant
decrease of the CXCL12 expression was observed starting from area A to end at area C, suggesting that CXCL12 is secreted along a decreasing
concentration gradient. (G) CXCL12 levels were evaluated by ELISA in conditioned media from SVZ, cerebellum, and olfactory bulb (OB) whole
mounts for 24 or 60 hours. (H) CXCL12 was expressed by astrocytes and endothelial cells within the adult SVZ. Immunostaining on organotypic
whole mounts showed a closely related expression of CXCL12 (green) with the vasculature and astrocytes (red). SVZ blood vessels and astrocytes
were respectively stained using a FITC-coupled lectin or a specific anti-GFAP antibody (red). Cell nuclei were counterstained with DAPI (blue). Scale
bars¼ 20 mm for C and D and 10 mm for E and H. Caption indicates where pictures and materials were taken.
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neurogenic zones of the adult brain, the SVZ, was able to spe-
cifically attract and host GSCs.3 We correlated this observation
with the fact that cancer stem cells often tend to hide in very
specific niches, which could help maintain their stem-like abil-
ities and capacity to drive tumor growth7,8 as well as influence
their intrinsic resistance to treatments.32 Moreover, this
Fig. 3. Expression of CXCR4 by various GBM cell types. (A) CXCR4 mRNA expression was found in 3 human GBM cell lines (U87MG, U373, and LN18)
and 2 human primary cultures (GBM 1 and 2). (B and C) Western blot analyses displayed a strong CXCR4 expression pattern in GBM cell lines and
primary cultures as well as in U87MG cells isolated from the tumor mass (U87MG-TM) or the SVZ (U87MG-SVZ) and U87MG floating gliomaspheres
(U87MG NS). (D) Human U87MG NS showed a combined expression of CXCR4 (red) with GFAP, Sox2, Nestin, and bIII-tubulin proteins (green). E)
U87MG-TM and U87MG-SVZ gliomaspheres specifically expressed CXCR4 (red) as well as GSC markers such as CD133 (green), Nestin (green), and
Integrin a6 (ITGA6) (pink). Nuclei were counterstained with DAPI (blue). Scale bars¼ 15 mm for D and E.
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Fig. 4. In vitro migration of GBM cells in response to recombinant CXCL12 and subventricular zone-conditioned medium (SVZ-CM). (A and B)
Recombinant CXCL12 triggered migration and chemotaxis of human U87MG cells. (C and D) SVZ-CM triggered migration and chemotaxis of
human U87MG cells. (E) The migration of U87MG cells and human GBM cells in primary culture (GBM2) in response to SVZ-CM was significantly
reduced by using AMD3100, a specific CXCR4 antagonist. (F) AMD3100 disrupted chemotaxis of U87MG cells in response to SVZ-CM. (G and H)
AMD3100 did not impact parameters such as the mean accumulated distance (mm) and velocity (mm/min) of U87MG cells. (I) U87MG-SVZ
cells showed greater migration abilities in response to recombinant CXCL12 and SVZ-CM compared with U87MG cells or U87MG-TM cells.
Moreover, AMD3100 clearly inhibited the migration of U87MG-SVZ cells in response to SVZ-CM. Graphs are mean values+SEM and are
representative of 3 independent experiments. *P, .05; **P, .01; ***P, .001; ns, not significant.
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observation creates an interesting parallel between GSCs and
neural stem cells, which also remain located in specific neuro-
genic zones in order to maintain their stem cell properties.33 A
recent clinical study strengthened the link between neurogen-
ic niches and malignant gliomas even more. This study
demonstrated that patients whose bilateral SVZs received
greater than the median SVZ radiation dose showed signifi-
cant improvement in progression-free survival.34 Taken to-
gether, these data suggest that the SVZ environment could
generously host and protect GSCs from radiation and
Fig. 5. Inhibition of the SVZ invasion by CXCR4-depleted U87MG cells. (A and B) Western blot and cytological analyses of the CXCR4 expression in
U87MGeGFP-Ires-Luc cells infected with lentiviruses encoding either a scrambled shRNA (U87MG-EIL-sc) or 2 short hairpins-RNA directed against
CXCR4 (U87MG-EIL-shCXCR4* and U87MG-EIL-shCXCR4**). CXCR4 expression was declined up to 41% in the U87MG-EIL-shCXCR4* cells and up to
64% in the U87MG-EIL-shCXCR4** cells. (C) CXCR4 knockdown also decreased the U87MG cells in vitro migration in response to recombinant
CXCL12 (1000nM) compared with the absence of CXCL12 (U87MG-EIL-sc CTL). (D and E) Animals were injected with either control U87MG cells
(U87MG-EIL-sc, n¼ 5 mice) or with CXCR4-depleted U87MG cells (U87MG-EIL-shCXCR4* and U87MG-EIL-shCXCR4**, n¼ 5 mice per group). Human
U87MG cells invaded the corpus callosum (CC) and the SVZ of mice grafted with U87MG-EIL-sc. No eGFP signal could be detected in the CC or the
SVZ of both shRNA conditions. Scale bars¼ 10 mm and 100 mm, respectively, for B and D-E. ***P, .001.
Goffart et al.: Role of CXCR4 in glioblastoma stem cells invasion
90
chemotherapy and therefore play a key role in GBM relaps-
es.35,36 We should also keep in mind that the cell of origin
for GBM, whether it derives from neural stem cells located in
the SVZ or another cell type, remains undefined to date.37 – 39
In this context, we decided to decipher the molecular mech-
anisms that underlie the oriented migration of GSCs to the
Fig. 6. AMD3100 inhibited the U87MG GSC invasion of the subventricular zone (SVZ). (A) AMD3100-treated animals showed significantly smaller
amounts of relative bioluminescence compared with the control group (P, .01) at the end of the treatment period. (B and C) Only a few U87MG
cells were found in the corpus callosum (CC) of AMD3100 treated-mice, whereas U87MG cells fully invaded the CC of PBS-treated mice (control).
U87MG cells could not be found in the SVZ area in AMD3100-treated animals, whereas U87MG cells from the control group invaded the SVZ as
expected. U87MG cells are labeled with a specific antihuman nuclei antibody. Scale bar¼ 100 mm for C. Graphs are mean values+SEM. **P, .01,
***P, .001.
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SVZ. Indeed, prospective identification and targeting of GSCs
seem mandatory to fully understand their biology, to counter-
act GBM relapses, and to develop new powerful therapeutic
strategies.
As a starting point, we hypothesized that chemokine recep-
tor CXCR4 would play a role. It is known that CXCR4 is expressed
by different types of cancer cells.9 This receptor is notably in-
volved in cancer cell proliferation and invasiveness.11,40 The ex-
pression level of CXCR4 is usually associated with a poor
prognosis in GBM patients12 and has been shown to be a key
mediator in GBM invasion.10 Recent findings showed that inhi-
bition of the CXCL12/CXCR4 autocrine/paracrine loop reduces
viability of human glioblastoma stem-like cells affecting self-
renewal activity.41 In this work, SVZ whole mounts showed a
staining pattern consistent with the expression of CXCL12 by
adult SVZ blood vessels and released in the nearby environ-
ment. Interestingly, it has also been suggested that GSCs are
maintained in vascular niches.42 We observed that the expres-
sion of CXCL12 in the SVZ is closely related to capillaries which,
in turn, have been shown to play a crucial role in maintaining
neural stem cell stemness in the adult brain.43,44 It could be
tempting to hypothesize that those capillaries are also active
on GSCs, notably by secreting CXCL12. In the same line, it has
recently been demonstrated that brain endothelial cells secrete
factors that are thought to support the expansion of GSCs by
recruiting the mTOR pathway.45 It would therefore be interest-
ing to examine the role of the mTOR pathway in GSC invasion as
a future perspective.
Human U87MG cells and GBM primary culture cells display
in vitro migration abilities in response to the SVZ soluble en-
vironment (SVZ-CM). This phenotype was shown to be par-
tially inhibited using AMD3100, a CXCR4-specific inhibitor.
That observation clearly suggested the eventual role played
by other chemokines in the SVZ-CM. Indeed, different mRNA
levels of chemokines were detected in the SVZ environment.
Several of those chemokines were found in the SVZ-CM as
well. A proteome profiler analysis showed that CXCL1 was
the most highly expressed chemokine in the SVZ-CM (Supple-
mentary data, Fig. S1). This new target could be really helpful
for better characterizing the controversial cell type responsi-
ble for the onset of gliomagenesis. CXCL1 has indeed been
shown to promote proliferation of early oligodendrocyte pro-
genitor cells,46 which in turn have recently been suggested to
be at the origin of malignant brain tumors.47 Consequently,
it would be worthwhile to investigate the status of CXCL1
as a target that might either support the CXCL12/CXCR4-
dependent migration of GSC to the SVZ or play another role
in GBM biology.
We also think it is mandatory to direct major attention to the
cancer cell population isolated from the SVZ. Those cells, locat-
ed away from the initial tumor mass, retain their ability to ini-
tiate development of new tumors when secondarily injected
into new animals and could therefore be at the origin of GBM
relapse.3 In-depth investigation on this cell subtype could pro-
vide tremendous new insights on the biology of cancer stem
cells. In vitro migration bio-assays showed that U87MG cells
isolated from the SVZ display enhanced migration abilities in re-
sponse to CXCL12 and SVZ-CM compared with U87MG cells iso-
lated from the tumor mass. Future analysis of the molecular
response to both stimulations in these 2 different cell subtypes
thus makes sense for a better understanding of the molecular
mechanisms that could lead GBM to systematically relapse and
to improve current treatments.
“Inhibition of the in vivo CXCL12/CXCR4 signaling, using ei-
ther lentiviral vectors allowing the expression of specific CXCR4
shRNAs or blocking CXCR4 with a specific antagonist
(AMD3100) led to the same observation: GSCs were not able
to home to the SVZ anymore.” Tumor volumes in the
AMD3100-treated animals were on average 28% smaller
than tumors in the control group but most importantly as
the main message of the present work, AMD3100 partially
blocked the CC invasion and prevented U87MG cells to reach
the SVZ environment. From a clinical aspect, the safety of
AMD3100 (also known as Plerixafor or Mozobil) has been eval-
uated in clinical trials25 and has raised great hope for new po-
tential clinical implications. This FDA-approved drug has
successfully been tested in patients with non-Hodgkin’s lym-
phoma and multiple myeloma, in order to support optimal
stem cell mobilization for autologous stem cell transplanta-
tion.48,49 Plerixafor, in combination with Avastin (an anti-VEGF
antibody) is now under intense investigation in a phase I clin-
ical trial with the aim of preventing the growth of recurrent
high-grade gliomas (NCT0133903950).
Taken together, our observations reported in the present
manuscript, as well as our previous work,3 have demonstrated
that the SVZ environment is able to attract and harbor GSCs via
the CXCL12/CXCR4 pathway. By this chemokine signaling sys-
tem, it is therefore tempting to speculate if neurogenic zones
in the adult brain may constitute a reservoir for tumor recur-
rence. Counteracting with the molecular mechanisms, which
drive the migration of GSCs to neurogenic zones, might there-
fore be of great importance for future definition of therapeutic
strategies.
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